NCT01609036
Terminated
Not Applicable
An Observational Phase IV Non Interventional Study in Patients With Advanced Follicular Lymphoma (III-IV) Evaluating the Safety of Maintenance Therapy With Rituximab After 8 Cycles of Rituximab in Combination With Chemotherapy as Induction Therapy in Previously Untreated Patients in Greece.
ConditionsLymphoma, Follicular
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lymphoma, Follicular
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 3
- Primary Endpoint
- Safety: Incidence of adverse events
- Status
- Terminated
- Last Updated
- 9 years ago
Overview
Brief Summary
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients, \>/=18 years
- •Patients with previously untreated follicular lymphoma (stage III-IV) according to the approved summary of product characteristics (SPC)
Exclusion Criteria
- •Contraindications to MabThera/Rituxan therapy according to the approved SPC
Outcomes
Primary Outcomes
Safety: Incidence of adverse events
Time Frame: 3 years
Secondary Outcomes
- Overall survival(3 years)
- Event-free survival(3 years)
- Progression-free survival(3 years)
Similar Trials
Completed
Not Applicable
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)Lymphocytic Leukemia, ChronicNCT01224093Hoffmann-La Roche219
Completed
Not Applicable
A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic LeukemiaLymphocytic Leukemia, ChronicNCT01609023Hoffmann-La Roche67
Completed
Not Applicable
An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid ArthritisRheumatoid ArthritisNCT01283399Hoffmann-La Roche79
Completed
Not Applicable
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT01684865Hoffmann-La Roche22
Completed
Phase 2
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT01392716Hoffmann-La Roche48